JP5570810B2 - 大腸癌マーカポリペプチド、及び大腸癌の診断方法 - Google Patents

大腸癌マーカポリペプチド、及び大腸癌の診断方法 Download PDF

Info

Publication number: JP5570810B2
Authority: JP; Japan
Prior art keywords: colorectal cancer; polypeptide; peptide; cancer marker; serum
Prior art date: 2007-08-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2009528951A

Other languages

English (en)

Japanese (ja)

Other versions

JPWO2009025080A1 (ja

Inventor

義男小寺

忠計前田

祐介川島

文夫野村

毅朝長

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kitasato Institute

Original Assignee

Kitasato Institute

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-18

Filing date

2008-08-15

Publication date

2014-08-13

2008-08-15 Application filed by Kitasato Institute filed Critical Kitasato Institute

2008-08-15 Priority to JP2009528951A priority Critical patent/JP5570810B2/ja

2010-11-18 Publication of JPWO2009025080A1 publication Critical patent/JPWO2009025080A1/ja

2014-08-13 Application granted granted Critical

2014-08-13 Publication of JP5570810B2 publication Critical patent/JP5570810B2/ja

Status Expired - Fee Related legal-status Critical Current

2028-08-15 Anticipated expiration legal-status Critical

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 242
206010009944 Colon cancer Diseases 0.000 title claims description 189
102000004196 processed proteins & peptides Human genes 0.000 title claims description 180
229920001184 polypeptide Polymers 0.000 title claims description 161
208000001333 Colorectal Neoplasms Diseases 0.000 title claims description 138
239000000439 tumor marker Substances 0.000 title claims description 100
238000002405 diagnostic procedure Methods 0.000 title description 5
210000002966 serum Anatomy 0.000 claims description 67
238000000034 method Methods 0.000 claims description 57
238000001356 surgical procedure Methods 0.000 claims description 11
238000003745 diagnosis Methods 0.000 claims description 9
238000004949 mass spectrometry Methods 0.000 claims description 9
102000014914 Carrier Proteins Human genes 0.000 claims description 5
108010078791 Carrier Proteins Proteins 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
230000000052 comparative effect Effects 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
125000004430 oxygen atom Chemical group O* 0.000 claims description 3
230000008569 process Effects 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 4
241000894007 species Species 0.000 claims 1
208000029742 colonic neoplasm Diseases 0.000 description 52
150000001413 amino acids Chemical group 0.000 description 50
238000001228 spectrum Methods 0.000 description 43
210000004027 cell Anatomy 0.000 description 37
239000003550 marker Substances 0.000 description 36
108090000623 proteins and genes Proteins 0.000 description 29
239000003153 chemical reaction reagent Substances 0.000 description 25
102000004169 proteins and genes Human genes 0.000 description 24
235000018102 proteins Nutrition 0.000 description 23
238000004458 analytical method Methods 0.000 description 21
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
238000001514 detection method Methods 0.000 description 18
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 16
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 13
125000000539 amino acid group Chemical group 0.000 description 13
239000000427 antigen Substances 0.000 description 13
102000036639 antigens Human genes 0.000 description 13
108091007433 antigens Proteins 0.000 description 13
210000001124 body fluid Anatomy 0.000 description 13
239000010839 body fluid Substances 0.000 description 13
238000004007 reversed phase HPLC Methods 0.000 description 13
239000000243 solution Substances 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
108010033276 Peptide Fragments Proteins 0.000 description 12
102000007079 Peptide Fragments Human genes 0.000 description 12
238000005259 measurement Methods 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
239000002299 complementary DNA Substances 0.000 description 10
239000012634 fragment Substances 0.000 description 10
239000002502 liposome Substances 0.000 description 10
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 10
239000006228 supernatant Substances 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 8
239000011259 mixed solution Substances 0.000 description 8
239000002773 nucleotide Substances 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
238000004445 quantitative analysis Methods 0.000 description 8
206010027476 Metastases Diseases 0.000 description 7
230000009401 metastasis Effects 0.000 description 7
239000013598 vector Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
239000000203 mixture Substances 0.000 description 6
239000003960 organic solvent Substances 0.000 description 6
108010005636 polypeptide C Proteins 0.000 description 6
230000007017 scission Effects 0.000 description 6
238000003756 stirring Methods 0.000 description 6
102100031752 Fibrinogen alpha chain Human genes 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
238000004885 tandem mass spectrometry Methods 0.000 description 5
238000002965 ELISA Methods 0.000 description 4
101710137044 Fibrinogen alpha chain Proteins 0.000 description 4
238000001816 cooling Methods 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
238000001574 biopsy Methods 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000010828 elution Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000007850 fluorescent dye Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000000575 proteomic method Methods 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
-1 t-butyloxycarbonyl Chemical group 0.000 description 3
238000012360 testing method Methods 0.000 description 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
238000009007 Diagnostic Kit Methods 0.000 description 2
102000048470 Dixin Human genes 0.000 description 2
108700037673 Dixin Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
241000700159 Rattus Species 0.000 description 2
241000256251 Spodoptera frugiperda Species 0.000 description 2
241000255993 Trichoplusia ni Species 0.000 description 2
102100023895 Zyxin Human genes 0.000 description 2
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
210000000628 antibody-producing cell Anatomy 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000027455 binding Effects 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
238000009534 blood test Methods 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000002052 colonoscopy Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000005112 continuous flow technique Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000005684 electric field Effects 0.000 description 2
230000002550 fecal effect Effects 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
229960004592 isopropanol Drugs 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
108010091748 peptide A Proteins 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
239000012071 phase Substances 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
108700001666 APC Genes Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
101100335652 Autographa californica nuclear polyhedrosis virus GP64 gene Proteins 0.000 description 1
108700040077 Baculovirus p10 Proteins 0.000 description 1
108060000903 Beta-catenin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000019399 Colonic disease Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
101150010917 GP67 gene Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000051366 Glycosyltransferases Human genes 0.000 description 1
108700023372 Glycosyltransferases Proteins 0.000 description 1
102000014702 Haptoglobin Human genes 0.000 description 1
108050005077 Haptoglobin Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
208000005016 Intestinal Neoplasms Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
241000255777 Lepidoptera Species 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
101100381978 Mus musculus Braf gene Proteins 0.000 description 1
241001045988 Neogene Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
101710182846 Polyhedrin Proteins 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
108010023249 Zyxin Proteins 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
238000010923 batch production Methods 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000003795 desorption Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
229940093541 dicetylphosphate Drugs 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
238000007865 diluting Methods 0.000 description 1
229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
235000006694 eating habits Nutrition 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
208000014617 hemorrhoid Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000002901 mesenchymal stem cell Anatomy 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229960002378 oftasceine Drugs 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
229920000352 poly(styrene-co-divinylbenzene) Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000004224 protection Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
108700042226 ras Genes Proteins 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Oncology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

JP2009528951A 2007-08-18 2008-08-15 大腸癌マーカポリペプチド、及び大腸癌の診断方法 Expired - Fee Related JP5570810B2 (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP2009528951A JP5570810B2 (ja)	2007-08-18	2008-08-15	大腸癌マーカポリペプチド、及び大腸癌の診断方法

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2007213211		2007-08-18
JP2007213211		2007-08-18
PCT/JP2008/002217 WO2009025080A1 (fr)	2007-08-18	2008-08-15	Polypeptide marqueur du cancer colorectal et procédé de diagnostic du cancer colorectal
JP2009528951A JP5570810B2 (ja)	2007-08-18	2008-08-15	大腸癌マーカポリペプチド、及び大腸癌の診断方法

Publications (2)

Publication Number	Publication Date
JPWO2009025080A1 JPWO2009025080A1 (ja)	2010-11-18
JP5570810B2 true JP5570810B2 (ja)	2014-08-13

Family

ID=40377989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2009528951A Expired - Fee Related JP5570810B2 (ja)	2007-08-18	2008-08-15	大腸癌マーカポリペプチド、及び大腸癌の診断方法

Country Status (2)

Country	Link
JP (1)	JP5570810B2 (fr)
WO (1)	WO2009025080A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2576610A4 (fr) *	2010-06-01	2014-03-05	Miraculins Inc	Biomarqueur pour le diagnostic et le traitement du cancer colorectal
JP2015108515A (ja) *	2013-12-03	2015-06-11	株式会社プロトセラ	大腸癌の診断のための検査方法
JP2016148623A (ja) *	2015-02-13	2016-08-18	京都府公立大学法人	大腸がんの検出方法
CN120958317A (zh) *	2023-03-30	2025-11-14	国立大学法人东海国立大学机构	信息处理装置、信息处理方法以及计算机程序

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004030615A2 (fr) *	2002-10-02	2004-04-15	Genentech, Inc.	Compositions et procedes de diagnostic et de traitement de tumeur
WO2004090550A2 (fr) *	2003-04-08	2004-10-21	Colotech A/S	Procede de detection d'un cancer colorectal dans des echantillons humains
WO2006125021A2 (fr) *	2005-05-16	2006-11-23	Dana Farber Cancer Institute, Inc.	Methodes de detection du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7504211B2 (en) *	2002-08-27	2009-03-17	Bristol-Myers Squibb Company	Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
WO2005054508A2 (fr) *	2003-12-01	2005-06-16	Ipsogen	Profilage de l'expression des genes dans le cancer du colon par microreseaux d'adn et correlation avec des parametres de survie et histocliniques
JP4916441B2 (ja) *	2004-08-13	2012-04-11	インディヴュームドゲゼルシャフトミットベシュレンクテルハフツング	結腸直腸腺腫及び／又は癌腫に対するバイオマーカーとしてのトランスサイレチンの使用；検出方法及び試験システム

2008
- 2008-08-15 WO PCT/JP2008/002217 patent/WO2009025080A1/fr not_active Ceased
- 2008-08-15 JP JP2009528951A patent/JP5570810B2/ja not_active Expired - Fee Related

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004030615A2 (fr) *	2002-10-02	2004-04-15	Genentech, Inc.	Compositions et procedes de diagnostic et de traitement de tumeur
WO2004090550A2 (fr) *	2003-04-08	2004-10-21	Colotech A/S	Procede de detection d'un cancer colorectal dans des echantillons humains
WO2006125021A2 (fr) *	2005-05-16	2006-11-23	Dana Farber Cancer Institute, Inc.	Methodes de detection du cancer

Also Published As

Publication number	Publication date
WO2009025080A1 (fr)	2009-02-26
JPWO2009025080A1 (ja)	2010-11-18

Publication	Publication Date	Title
KR102596374B1 (ko)	2023-10-30	대장암을 검출하기 위한 바이오마커
US10539576B2 (en)	2020-01-21	Lung cancer differential marker
KR101431062B1 (ko)	2014-08-21	유방암 진단용 다중 바이오마커 세트, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트
US20120077696A1 (en)	2012-03-29	Soluble hla complexes for use in disease diagnosis
EP2281201A1 (fr)	2011-02-09	Procédé permettant la découverte de biomarqueurs et de cibles de médicaments en vue du diagnostic et du traitement du cancer de la prostate et dosages de biomarqueurs déterminés avec ce procédé
US20090053828A1 (en)	2009-02-26	Detection of glycopeptides and glycoproteins for medical diagnostics
US8642347B2 (en)	2014-02-04	Urinary CA125 peptides as biomarkers of ovarian cancer
JP5570810B2 (ja)	2014-08-13	大腸癌マーカポリペプチド、及び大腸癌の診断方法
Dudas et al.	2009	Usage of cancer associated autoantibodies in the detection of disease
KR101527283B1 (ko)	2015-06-10	당단백질의 탈당화 검출을 통한 암 마커 스크리닝 방법 및 간세포암 마커
US9372189B2 (en)	2016-06-21	Biomarker for lymphocytic infundibuloneurohypophysitis, and use applications thereof
JP5090332B2 (ja)	2012-12-05	炎症及び感染症のためのバイオマーカーとしての短鎖ｓｒｌアルコールデヒドロゲナーゼ（ｄｈｒｓ４）の測定
EP4059954A1 (fr)	2022-09-21	Procédé, kit et biomarqueur pour aider au diagnostic du cancer du côlon
WO2015026909A2 (fr)	2015-02-26	Essai de msia-srm pour l'analyse de biomarqueur
KR102131860B1 (ko)	2020-07-08	아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
KR101431067B1 (ko)	2014-08-21	유방암 진단용 단백질 마커 아포리포단백질 （ａ）, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트
KR101231235B1 (ko)	2013-02-08	전립선암 줄기세포 선별용 단백질성 마커
KR101819939B1 (ko)	2018-01-19	유방암 진단용 단백질 마커 베타-투 마이크로글로불린 및 이를 검출하는 방법
KR101431066B1 (ko)	2014-08-21	유방암 진단용 단백질 마커 파이브로넥틴, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트
KR101431064B1 (ko)	2014-08-21	유방암 진단용 단백질 마커 탄산탈수효소 1, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트
KR100882231B1 (ko)	2009-02-06	유방암 진단용 단백질 마커 플라빈 환원효소 및 이에 대한항체를 포함하는 유방암 진단키트
Castillo	2015	Mass Spectrometry-Based Approaches for Targeted Quantitative Proteomics in Biomarker Development

Legal Events

Date	Code	Title	Description
2011-08-12	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110811
2011-09-17	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110831
2013-09-03	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130903
2013-11-02	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131101
2013-11-12	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131111
2013-11-29	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131128
2014-05-22	TRDD	Decision of grant or rejection written
2014-05-28	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140527
2014-07-03	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140625
2014-07-04	R150	Certificate of patent or registration of utility model	Ref document number: 5570810 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2017-07-04	LAPS	Cancellation because of no payment of annual fees